Company news: Alembic Pharmaceuticals

| Updated on December 02, 2019

Alembic Pharmaceuticals on Monday announced that its joint venture Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application Diclofenac Sodium Topical Solution USP, 2% w/w. The drug is indicated for the treatment of the pain of osteoarthritis of the knees. Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of $974 million for 12 months ending December 2018, according to IQVIA. Shares of Alembic Pharma closed 0.48 per cent higher at ₹554.90 on the BSE.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on December 02, 2019
This article is closed for comments.
Please Email the Editor